slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 203,341-203,370
Pages 10,126
Rows per page 30
Component
203,341-203,370 of 303,780
29
The slide uses a checkmark matrix to highlight the competitive advantage of the company's drug candidate.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
30
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
31
Uses a combination of a map, metric callouts, and a vertical process-style list to convey urgency.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
34
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
35
The slide uses a card-based layout to detail the value proposition and operational structure of four distinct entities.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
01
Corporate mission statement slide.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
02
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
04
Includes a specific date reference at the bottom: October 25, 2022.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Situation & Context1 hit
06
The slide uses a Gantt-style visualization to represent clinical trial progress for various drug candidates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · AgitationLoop · Cost Of Inaction1 hit
07
The slide uses a horizontal arrow timeline to organize clinical trial phases and results.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · AgitationLoop · Cost Of Inaction1 hit
08
Slide 08 in a presentation deck.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
09
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
10
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses chemical structure diagrams to illustrate the relationship between the racemate and its enantiomers.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
Data source: Zanos et al., 2016. The charts show dose-dependent reduction in immobility time.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
CADSS = Clinician administered dissociative states scale. Data points are clustered by time interval.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a list of three key regulatory takeaways followed by a forward-looking implication for the pipeline.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide introduces the drug candidate VLS-01, providing its chemical identity and current clinical trial status.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
26
The slide uses a process flow diagram to represent clinical trial cohorts and SMG (Safety Monitoring Group) review gates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit